drugset / Trial / NCT01237327

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

NCT01237327

Phase 3 Completed 84 enrolled Pfizer
Parallel-groupOpen-labelTreatment

Summary

Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.

Timeline

Start
2001-11
Primary completion
2007-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Exemestane Small molecule 25 mg Oral
Comparator Megestrol Acetate Other / unclassified 160 mg Oral

Indications